Skip to main content

Table 2 Rivaroxaban plasma concentrations after therapeutic doses based on phase II data and simulated virtual data

From: Laboratory assessment of rivaroxaban: a review

Dose Clinical setting Ctrough(μg/l) Cmax(μg/l)
2.5 mg bid Acute coronary syndrome 16 (6–34)* 44 (28–66)*
10 mg od VTE prevention after total hip replacement 9 (1–38)# 125 (91–196)#
15 mg od Stroke prevention in patients with AF (CrCl ≤50 ml/min) 57 (18–136) 229 (178–313)
20 mg od DVT treatment (continued treatment) 26 (6–87)§ 270 (189–419)§
20 mg od Stroke prevention in patients with AF (CrCl >50 ml/min) 44 (12–137) 249 (184–343)
  1. *Estimated parameters at steady state – median values (5th–95th percentile range) [18]. #Estimated parameters at steady state – median values (5th–95th percentile range) in patients undergoing hip replacement surgery [46]. Estimated parameters at steady state – geometric means (5th–95th percentile range) in stroke prevention in patients with AF (Bayer HealthCare Pharmaceuticals and Janssen Research & Development, LLC: data on file). §Estimated parameters at steady state – geometric means (5th–95th percentile range) in phase II studies in the acute treatment of DVT [19].
  2. Abbreviations: AF atrial fibrillation, bid: twice daily, C max maximum plasma concentration, CrCl creatinine clearance, C trough minimum plasma concentration, DVT deep vein thrombosis, od once daily, VTE venous thromboembolism.